Develop pharmaceutical botanical medicines. Formulate medicines with highly bioavailable plant extracts. Now — the numbers.
There is not enough trading history here to call this an established business.
Red columns mark years that ended in a loss.
The gap is $62K. In times of high interest rates, a gap like that can squeeze a company.
The market pays 22.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 66% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
The stock sits at $0.0058. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.